Hefei Lifeon Pharmaceutical Co Ltd (003020) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hefei Lifeon Pharmaceutical Co Ltd (003020) has a cash flow conversion efficiency ratio of 0.343x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥667.63 Million ≈ $97.69 Million USD) by net assets (CN¥1.95 Billion ≈ $284.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hefei Lifeon Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Hefei Lifeon Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Hefei Lifeon Pharmaceutical Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Hefei Lifeon Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hefei Lifeon Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vivakor Inc
NASDAQ:VIVK
|
0.176x |
|
Ningbo Bohui Chemical Technology
SHE:300839
|
-0.143x |
|
Xiamen Sunrise Wheel Group Co Ltd
SHE:002593
|
0.029x |
|
Leong Hup International Berhad
KLSE:6633
|
0.073x |
|
Xinjiang Ba Yi Iron & Steel Co Ltd
SHG:600581
|
-1.880x |
|
EirGenix
TWO:6589
|
-0.020x |
|
APG SGA SA
SW:APGN
|
0.000x |
|
Shanghai Yimin Commerce Group Co Ltd
SHG:600824
|
0.008x |
Annual Cash Flow Conversion Efficiency for Hefei Lifeon Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Hefei Lifeon Pharmaceutical Co Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Hefei Lifeon Pharmaceutical Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.91 Billion ≈ $279.87 Million |
CN¥197.53 Million ≈ $28.91 Million |
0.103x | -5.00% |
| 2023-12-31 | CN¥1.87 Billion ≈ $274.15 Million |
CN¥203.67 Million ≈ $29.80 Million |
0.109x | -19.80% |
| 2022-12-31 | CN¥1.48 Billion ≈ $216.60 Million |
CN¥200.64 Million ≈ $29.36 Million |
0.136x | +11.37% |
| 2021-12-31 | CN¥1.30 Billion ≈ $190.80 Million |
CN¥158.70 Million ≈ $23.22 Million |
0.122x | -17.16% |
| 2020-12-31 | CN¥1.17 Billion ≈ $171.79 Million |
CN¥172.49 Million ≈ $25.24 Million |
0.147x | -41.94% |
| 2019-12-31 | CN¥590.00 Million ≈ $86.34 Million |
CN¥149.30 Million ≈ $21.85 Million |
0.253x | +98.55% |
| 2018-12-31 | CN¥505.70 Million ≈ $74.00 Million |
CN¥64.45 Million ≈ $9.43 Million |
0.127x | +307.11% |
| 2017-12-31 | CN¥361.71 Million ≈ $52.93 Million |
CN¥11.32 Million ≈ $1.66 Million |
0.031x | -84.18% |
| 2016-12-31 | CN¥298.09 Million ≈ $43.62 Million |
CN¥58.99 Million ≈ $8.63 Million |
0.198x | -53.66% |
| 2014-12-31 | CN¥215.53 Million ≈ $31.54 Million |
CN¥92.05 Million ≈ $13.47 Million |
0.427x | +112.57% |
| 2013-12-31 | CN¥176.88 Million ≈ $25.88 Million |
CN¥35.54 Million ≈ $5.20 Million |
0.201x | +458.44% |
| 2012-12-31 | CN¥141.96 Million ≈ $20.77 Million |
CN¥-7.96 Million ≈ $-1.16 Million |
-0.056x | -- |
About Hefei Lifeon Pharmaceutical Co Ltd
Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethy… Read more